Navigation Links
IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
Date:2/5/2008

On February 5, 2008, the closing price of the Company's common stock was

$3.81 per share

IRVINE, Calif., Feb. 5 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that it received a letter, dated February 4, 2008, from The NASDAQ Stock Market, notifying IDM Pharma that during the preceding 30 consecutive business days, the closing bid price of the Company's common stock had been below the $1.00 minimum bid per share required for continued listing on the NASDAQ Global Market under NASDAQ Marketplace Rule 4450(a)(5).

The NASDAQ letter dated February 4, 2008 has no immediate effect on the listing of the Company's common stock. On February 5, 2008, the closing price of the Company's common stock was $3.81 per share.

In accordance with NASDAQ Marketplace Rule 4450(e)(2), the Company will be granted 180 calendar days, or until August 4, 2008, to regain compliance with the minimum bid price requirement in accordance with NASDAQ Marketplace Rule 4450(a)(5) by maintaining a closing bid price of $1.00 per share or higher for a minimum of 10 consecutive trading days. If the Company is successful in meeting this requirement, NASDAQ will provide written notification that is has achieved compliance with the Rule. If the Company is unsuccessful in meeting the minimum bid requirement during this initial 180-day period, NASDAQ will provide notice to IDM Pharma that the Company's common stock will be delisted from the NASDAQ Global Market. If the Company receives a delisting notification, the Company may appeal to the Listing Qualifications Panel or apply to transfer its common stock to the NASDAQ Capital Market if IDM Pharma satisfies all criteria for initial listing on the NASDAQ C
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference
2. MAP Pharmaceuticals Announces Resignation of Chief Medical Officer
3. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
4. ARMSRx Tackles the New Rx Addiction -- Pharmacy Benefit Audits
5. NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
6. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
7. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
8. Poniard Pharmaceuticals Announces Upcoming Conference Participation
9. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
10. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
11. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and ... under $150 . All these items are brand new; they ... already been updated with the new range of high quality ... far. All iFitDress.com’s designs are made according to the latest ... materials. Every outfit from the company is handpicked by skilled ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 New studies reveal ... to hearing loss related depression (March 6, 2014, JAMA Otolaryngology*). ... gradual hearing loss (about 50 percent according to recent polls) ... effect on how a person feels and relates to the ... overall improvements are also made by way of:, ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Dr. Vu ... the expansion of his practice and med-spa with the ... practice’s growing list of cosmetic treatments and services. , ... into the skin,” says Dr. Ho. “As a result ... such as wrinkles, sun spots, discolorations or blemishes.” , ...
(Date:12/24/2014)... December 24, 2014 The federal ... allege the blood thinner caused life-threatening episodes of ... leadership structure for the proceeding, Bernstein Liebhard LLP ... the Court plans to select lawyers to serve ... plans on appointing a Plaintiffs’ Steering Committee, which ...
Breaking Medicine News(10 mins):Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3
... April 4, 2008 Companies align,commercial and portfolio ... an annual sales volume of $10 to 20 ... the early-stage commercialization team along,with approximately eight portfolio ... is approximately four to three, commercial to,portfolio management ...
... Lilly and Company,(NYSE: LLY ) today announced ... for FORSTEO(R) (teriparatide [rDNA origin] injection) for the,treatment ... women and men at increased risk for fracture.,This ... February by,the Committee for Medicinal Products for Human ...
... 3, 2008 To promote,the U.S. Department ... for a,Healthy Future" initiative, Acting U.S. Surgeon ... visited with several community leaders at A.I.,DuPont ... in reducing,childhood obesity in Delaware., (Photo: ...
... Targeted mass,media campaigns alone can be effective ... to adopt safer,sex practices, according to a ... the University of Kentucky with funding from ... public health campaigns, particularly those promoting healthy,behaviors, ...
... Security determined outcome of ,terrible 2s, battles but not ... News) -- The way mothers and their 2-year-olds relate ... the frequency -- of conflict during the "terrible twos." ... quality and frequency of such conflicts, according to a ...
... Plus, meet and greet fitness and figure professionals, PITTSBURGH, April 3, 2008 , ... Frahn WHAT: The MORE ... of the More Magazine Marathon and Half-Marathon) WHEN: 12 -7 p.m. April ... 135 W. 18th Street, New York (between 6th and 7th ...
Cached Medicine News:Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 3Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 4Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 5Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 2Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 3Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 2Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 3Health News:Mother-Child Bond Affects Quality of Conflict Resolution 2Health News:GNC to Run Sweepstakes, Raffle Fitness Equipment at MORE Magazine Health and Wellness Expo 2
(Date:12/24/2014)... SAN DIEGO , Dec. 24, 2014 /PRNewswire/ ... the West, developing the proprietary Natural Killer (NK) ... announces that Dr. Patrick Soon-Shiong , NantWorks ... into a definitive agreement to purchase approximately $48 ... In connection with the investment, he will be ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 /PRNewswire/ ... biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for ... need and commercial potential, today announced that it ... shares of its common stock and Series C ... stock.  Funds under the management of QVT Financial ...
(Date:12/24/2014)... PuraMed BioScience®, Inc., (OTC Pink: PMBS), a ... healthcare products, announced it received the initial funding to ... headache relief product, for planned distribution to 1,000 medical ... , Washington State , and ... H Advanced headache relief gel formulation completed, PuraMed BioScience ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... Breast-Specific Gamma Imaging (BSGI) has been proven to be ... carcinoma in situ (DCIS), a difficult to diagnose breast cancer. ... lesions independent of tissue density and discover very early stage ... of the Radiological Society of North America (RSNA), BSGI is ...
... Nov. 30 Covance Inc. (NYSE: CVD ) today ... Health Care Conference on Wednesday, December 2, 2009 at 1:30 p.m. ... at www.covance.com . In order to register and download ... with headquarters in Princeton, New Jersey, is one of the world,s ...
Cached Medicine Technology:Breast-Specific Gamma Imaging Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: